bioAffinity Technologies Secures $1.8 Million Financing Through WallachBeth Capital

In a significant move to bolster its financial standing and support its mission of advancing noninvasive cancer testing, bioAffinity Technologies, Inc. has successfully negotiated a financing agreement totaling approximately $1.8 million. This arrangement was facilitated by WallachBeth Capital, LLC, a recognized leader in capital markets services. The financing entails the sale of 720,000 shares of common stock at a price of $2.50 per share, effectively aligning with at-the-market offerings under Nasdaq guidelines.

Key Details of the Offering

This latest financing will enable bioAffinity Technologies to uphold its operational continuity, particularly as it seeks to expand its market reach with the CyPath® Lung test—a noninvasive diagnostic tool aimed at detecting lung cancer at early stages. Closing of the transaction is anticipated on or around October 9, 2025, contingent on fulfilling standard closing criteria.

The gross revenue from this deal is expected to empower the company’s working capital while catering to the anticipated growth in sales related to its pioneering diagnostic solutions. The firm is utilizing funds primarily for general corporate needs, underscoring its commitment to innovation in cancer detection technologies.

The Role of WallachBeth Capital

WallachBeth Capital’s role as the sole placement agent underscores the firm's expertise in facilitating investment transactions that cater to the health tech sector. As a broker-dealer, WallachBeth is known for its advisory and execution services in various capital market activities, including initial public offerings and private placements. Their adept handling of this financing signifies a solid partnership aimed at elevating bioAffinity’s financial capabilities and operational agility.

Future Prospects and Company Vision

Moving forward, bioAffinity Technologies is optimistic about the potential impact that this capital infusion will have not only on its growth trajectory but also on its ability to innovate in cancer diagnostics. There is a growing urgency for noninvasive tests like CyPath, which promise earlier and more accurate detection of cancers, and this funding is integral to achieving these objectives.

As the company embarks on this new chapter, it has emphasized its commitment to expanding access to important diagnostic tools that could improve patient outcomes fundamentally. The successful execution of this financing is a critical step toward realizing that vision.

About bioAffinity Technologies

Founded with the goal of creating noninvasive cancer tests, bioAffinity Technologies has committed itself to revolutionizing cancer detection for better diagnostic solutions. Its proprietary technology aims to provide patients with earlier diagnoses, thus enhancing treatment possibilities and outcomes. This financing will undoubtedly support their ongoing efforts in the biotechnology landscape, paving the way for advancements in cancer detection technologies.

Conclusion

bioAffinity Technologies’ collaboration with WallachBeth Capital marks a strategic financial undertaking designed to enhance the company's capabilities in the healthcare market. As it moves forward with the development of innovative diagnostic solutions, this financing represents both an opportunity and a commitment to improve healthcare outcomes through technology-driven approaches. With its sights set on impacting the lives of patients and healthcare providers alike, bioAffinity Technologies is positioned to make significant strides in the field of cancer diagnostics.